Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Fulvestrant With or Without Ganetespib in HR+ Breast Cancer

This study is currently recruiting participants. (see Contacts and Locations)
Verified November 2014 by Dana-Farber Cancer Institute
Sponsor:
Information provided by (Responsible Party):
Nancy Lin, MD, Dana-Farber Cancer Institute
ClinicalTrials.gov Identifier:
NCT01560416
First received: February 21, 2012
Last updated: November 18, 2014
Last verified: November 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: No date given
  Estimated Primary Completion Date: February 2015 (Final data collection date for primary outcome measure)